Tisagenlecleucel

Names

[ CAS No. ]:
1823078-37-0

[ Name ]:
Tisagenlecleucel

Biological Activity

[Description]:

Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma[1][2].

[Related Catalog]:

Research Areas >> Cancer
Signaling Pathways >> Others >> Others
Research Areas >> Inflammation/Immunology

[In Vivo]

Tisagenlecleucel 靶向并清除表达 CD19 的 B 细胞，显示出对 B 细胞淋巴瘤的疗效[1]。

[References]

[1]. Bishop MR, et, al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2022 Feb 17;386(7):629-639.  

[2]. Fowler NH, et, al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022 Feb;28(2):325-332.  

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.